Thursday, April 27, 2017 2:26:45 AM
It's either a yes or no?
What is your opinion?
I did go to Investopedia , *before* I posted.
A two week C & H, AS POSTED, does not fit the minimum 7 week time frame ( per investopedia ) , a difference of 350%.
Check Bill O'Neil of IBD for his thoughts on C&H
I also used a line chart and a mountain chart. Both make the cup bottom look different.
What do you see as the "expected" up price movement?
Do you see more than a 2 cent up move?
**As for the .06 - .18 move; did T.A. predict that ?**
I was watching that day and can tell you that there was a "bear raid" that started at 3:00 PM and ended at 3:30 PM.
Why???
At .18 warrants could be exercised.
**Exercised warrants = money going to the company.**
I don't remember how many warrants could have been exercised. I think it was $ 2M worth ( The correct amounts are in a 10K) .
About 5 weeks later the company was forced to raise funds by selling shares at .12.
Who benefited ??
*Not shareholders*, it cost 50% more per share to raise an equal amount of money.
You are free to post as am I .
Having different points of view is OK.
**I am in no way interfering with what you post or how you trade.**
IMO: Without any further news ; the current price may decline.Should be interesting to see Mondays close.
BTW: There are trading platforms/software that can go back in time and replay each and every trade , including time , price & volume.NOT exchange, UP to 4PM.
ALSO: Often , several times a week there is a last/close of day trade at 4:02:01 by Amex.
That last trade is the only one viewed by many traders .
AND ; for me, this is a risk/reward investment. My risk is known and acceptable.
For me; Bio's are "feast or famine" with this one being being a good "risk/reward".
The reward is ; With FDA H&N approval ,treating just 31% of the 650,00 ANNUAL patients = 200,000 X $50,000 = $ 10 B per year in gross sales.
IMO: Using a 20 SMA shows short periods above the 20SMA, that would make this an in & out stock, without any long term tax advantages.
IMO:The P3 *may* actually ,already been completed.
****880,784,298.****
Recent CVM News
- CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results • Business Wire • 05/16/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:17:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 01:04:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 05:07:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 01:19:04 PM
- CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer • Business Wire • 05/08/2024 01:00:00 PM
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors • Business Wire • 04/23/2024 01:00:00 PM
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology • Business Wire • 03/19/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/07/2024 04:33:42 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 04:33:13 PM
- CEL-SCI Corporation Issues Letter to Shareholders • Business Wire • 03/06/2024 01:45:00 PM
- CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results • Business Wire • 02/15/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:31:12 PM
- CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/13/2024 05:00:00 PM
- CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/09/2024 01:30:00 PM
- CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug • Business Wire • 02/06/2024 02:00:00 PM
- European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® • Business Wire • 01/31/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:06:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:00:11 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/22/2023 09:01:06 PM
- CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments • Business Wire • 12/22/2023 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/21/2023 09:15:39 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM